Cargando…
Infliximab versus cyclosporine for severe ulcerative colitis refractory to steroids: A protocol for systematic review and meta-analysis
BACKGROUND: Infliximab and cyclosporine are two main therapies in treating acute severe ulcerative colitis (ASUC), our objective is to assess the effectiveness and safety of cyclosporine (CSA) versus infliximab (IFX) as rescue agents in patients with steroid-refractory ulcerative colitis (UC). METHO...
Autores principales: | Wu, Dongjie, Yang, Zhen, Zhao, Chen, Yao, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203526/ https://www.ncbi.nlm.nih.gov/pubmed/30313056 http://dx.doi.org/10.1097/MD.0000000000012657 |
Ejemplares similares
-
Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis
por: Szemes, Kata, et al.
Publicado: (2020) -
Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study
por: Kim, Eun Hye, et al.
Publicado: (2015) -
Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis
por: Jia, Xuemei, et al.
Publicado: (2020) -
Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis
por: Feuerstein, Joseph D., et al.
Publicado: (2016) -
Successful cyclosporin and ustekinumab combination therapy in a
patient with severe steroid-refractory ulcerative colitis
por: Ganzleben, Ingo, et al.
Publicado: (2020)